OTC:AKBLF ALK-Abelló A/S (AKBLF) Stock Price, News & Analysis $28.95 -1.49 (-4.89%) As of 07/29/2025 02:25 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About ALK-Abelló A/S Stock (OTC:AKBLF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ALK-Abelló A/S alerts:Sign Up Key Stats Today's Range$28.95▼$28.9550-Day Range$25.95▼$30.5352-Week Range$19.90▼$30.53Volume1 shsAverage Volume269 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark. Read More Receive AKBLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALK-Abelló A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBLF Stock News HeadlinesALK-Abelló A/S (AKBLF) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comALK Abello: ITULATEK approved for treatment of children and adolescents in CanadaMay 10, 2025 | finanznachrichten.deNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system tracks breaking AI news and shows when to trade.📈 AI-backed. Beginner-friendly. Results proven.July 30 at 2:00 AM | Timothy Sykes (Ad)ARS Pharma in pact with ALK-Abelló to co-promote neffyMay 2, 2025 | seekingalpha.comALK-Abello says FDA approves label expansion for OdactraFebruary 28, 2025 | markets.businessinsider.comReport on transactions with ALK-Abelló A/S B shares and associated securities by managerial staffFebruary 21, 2025 | finance.yahoo.comAlk-Abello AS (AKBLF) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ExpansionFebruary 20, 2025 | finance.yahoo.comALK Abello: Annual report 2024: ALK delivers 15% sales growth with profits up 65%February 19, 2025 | finanznachrichten.deSee More Headlines AKBLF Stock Analysis - Frequently Asked Questions How have AKBLF shares performed this year? ALK-Abelló A/S's stock was trading at $22.35 at the beginning of 2025. Since then, AKBLF shares have increased by 29.5% and is now trading at $28.95. How do I buy shares of ALK-Abelló A/S? Shares of AKBLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:AKBLF CIKN/A Webwww.alk.net Phone45.45.74.75.76FaxN/AEmployees2,824Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTC:AKBLF) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALK-Abelló A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share ALK-Abelló A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.